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Polymorphism of the cytokine genes and IgA nephropathy. renal insufficiency, hypertriglyceridemia and hyperuri-
Background. IgA nephropathy (IgAN) is a form of chronic cemia at the time of diagnosis, are associated with pro-
glomerulonephritis of unknown etiology and pathogenesis. Cy- gression of IgAN [1–3]. The cause of IgAN is unknown,tokine gene polymorphisms regulate cytokine production and
as are the factors increasing susceptibility to IgAN.play a role in immune and inflammatory responses; these immu-
The clinical presentation of IgAN is variable. Grossnological responses thus are possibly involved in the etiology
and pathogenesis of IgAN. hematuria episodes coinciding recurrently with microbial
Methods. We studied by polymerase chain reaction (PCR) infections or other antigenic challenge is a typical mani-
polymorphisms of important cytokine genes of inflammation festation. Another common finding is microscopic hema-interleukin-1 (IL-1b), tumor necrosis factor- (TNF-a), interleu-
turia with or without proteinuria [1]. The mode by whichkin-6 (IL-6), and interleukin-1 receptor antagonist (IL-1Ra) in
various antigenic challenges affect IgAN is unknown. It167 patients with IgAN and 400 healthy blood donor controls.
IgAN patients had been followed up for 6 to 17 (median 11) is suspected that the disorder is somehow connected with
years from renal biopsy. mucosal immune response and that the systemic IgA
Results. Carriage of the IL-1b allele 2 (IL1b2) or IL-1Ra
response is abnormal. Several microbial or dietary anti-allele 2 (IL1RN*2) was associated with an increased risk of
gens are possibly of significance in the pathogenesis ofIgAN. These alleles were highly linked and the odds ratio (OR)
of IgAN for carriage of both alleles was 1.8 (95% confidence IgAN in susceptible persons [4]. Genetic factors are
interval 1.2 to 2.6; P  0.002). Carriage of the TNF-a allele 2 likely to contribute to the development and progression
(TNF2) was associated with a decreased risk of IgAN (OR 0.5, of IgAN [5]. Gharavi and coworkers recently demon-
range 0.3 to 0.7; P  0.001). The risk of IgAN was found to
strated by a genome-wide analysis linkage of IgAN tobe highest in those carrying IL1b2 and IL1RN*2 but not TNF2
chromosome 6q22-q23 [6].as compared to those who did not carry both of these IL-1
cluster genes and were carriers of TNF2 (OR 5.0 (2.4–10.3); Interleukin (IL-1) and tumor necrosis factor- (TNF-)
P 0.001). None of the polymorphisms studied was associated are pro-inflammatory cytokines, and the IL-1 receptor
with poor prognosis. antagonist (IL-1Ra) is anti-inflammatory, while interleu-Conclusion. Carriage of IL1b2 and IL1RN*2 together with
kin-6 (IL-6) has both of these properties. The networknon-carriage of TNF2 is associated with increased susceptibil-
of cytokines should function at an optimal level to guar-ity, but not with a prognosis of IgAN.
antee the successful eradication of antigens and to avoid
excessive damage to the host. The development of glo-
merular inflammation in IgAN has been associated withIgA glomerulonephritis (IgAN) is an immune-medi-
various cytokines [7–10]. Cytokines produced during in-ated disorder and the most frequent type of glomerulo-
fections or other antigenic challenges may play a role innephritis in humans [1, 2]. Its clinical course is variable,
the pathogenesis of IgAN. One explanation is that hostranging from spontaneous clinical remission to terminal
renal failure. About 10 to 20% of IgAN patients progress genetic factors in conjunction with infections and/or en-
to end-stage renal disease (ESRD) within 10 years [1, 2]. vironmental factors determine the immune and inflam-
Several factors, for example hypertension, proteinuria, matory responses to the unknown antigen(s). Cytokines
also operate in the proliferation and differentiation of
lymphoid cells. Patients with IgAN have an increased
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memory repertoire of IgA1-producing B-lymphocytes infactor, glomerulonephritis, IgA nephropathy, immune response, pro-
gressive renal disease, renoprotection. their bone marrow together with high plasma levels of
IgA1 [11]. Major effects of the cytokines IL-1 and TNF-Received for publication April 25, 2001
include T- and B-cell help, with IL-1Ra blocking theand in revised form August 31, 2001
Accepted for publication September 29, 2001 activity of IL-1, while IL-6 affects B-cell differentiation
and maturation. 2002 by the International Society of Nephrology
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Cytokine genes are polymorphic and their polymor- METHODS
phism may influence the levels of corresponding cyto- Patients and controls
kines [12, 13]. The IL-1 gene cluster on chromosome 2 All subjects were Caucasians from the area of Pirkan-
(2q12-q21) [13] contains three related genes within a maa, Finland. Data on the patients have recently been
430 kilobase region, which encode the proinflammatory described [3]. Briefly, the original patient population
cytokines IL-1 and IL-1 as well as their endogenous consisted of all 223 IgAN patients diagnosed between
receptor antagonist IL-1Ra. Carriage of the more infre- January 1980 and December 1990 in Tampere Uni-
quent allele 2 of the IL-1 gene at position511 (IL1b2) versity Hospital, which serves the area of Pirkanmaa with
is associated with increased IL-1 production [12], and 440,000 inhabitants. The indications for renal biopsy were:
carriage of IL-1Ra allele 2 (IL1RN*2) with increased microscopic hematuria and proteinuria (0.15 g/24 h)
in 179 patients, microscopic hematuria alone in 28, pro-production of IL-1Ra [14]. The enhancing effect of
teinuria without hematuria in 13 and acute renal failureIL1RN*2 on plasma IL-1Ra levels requires the presence
in three. Six patients had nephrotic syndrome and 78of IL1b2, which implies that the IL-1b gene participates
(35%) patients had a history of gross hematuria. Duringin the regulation of IL-1Ra production [14]. TNF genes
the follow-up period, 30 of the original patients died andlocate on chromosome 6 (6p21.3) [13]. Carriage of the
15 moved away from Pirkanmaa. The 178 patients stillmore infrequent allele 2 of the TNF gene at position
living in the area were invited to attend for assessment308 (TNF2) has been linked to increased TNF tran-
between October 1996 and January 1997; 168 (94%)scription in vitro [15, 16], but contradictory results are
agreed to participate. DNA could be extracted fromalso reported [17, 18]. IL-6 gene locates on chromosome
whole blood samples from all but one of these 168 pa-7 (7p21-p14) [13]. IL-6 gene G/C polymorphism at posi-
tients. Thus, the study population comprised 167 pa-
tion 174 also is located in the promoter region of the
tients, 102 (61%) of whom were men and 65 (39%)
gene and carriage of the C allele has been associated women. Their mean age (range) at the time of renal
with decreased IL-6 levels [19]. biopsy was 38 (8 to 78) years. The median follow-up
Genetic polymorphisms of IL-1 (a and b), TNF (a and time (range) from biopsy was 11 (6 to 17) years and
b) and IL-1Ra are implicated in several inflammatory from the first signs of IgAN (episode of macroscopic
diseases [12, 20], such as alopecia areata, rheumatoid hematuria, discovery of microscopic hematuria, or pro-
arthritis and systemic lupus erythematosus. The carriage teinuria or renal insufficiency) 14 (6 to 57) years. Since
rate of IL1RN*2 has been reported to be higher in dia- diagnosis the patients have been under the control of
betic patients with nephropathy than in those without our hospital or a local health care center. Data on medi-
nephropathy [21]. IL-1Ra gene polymorphism in IgAN cation, occurrence of gross hematuria, blood pressure,
has been reported in two recent studies [22, 23]. Shu and 24-hour urinary protein excretion and serum creatinine
were studied at the time of renal biopsy and at the assess-colleagues found an excessive carriage of IL1RN*2 in
ment visit.patients as compared to healthy controls [23], whereas
There were no cases of systemic lupus erythematosusno such association was found in an earlier study [22].
or liver cirrhosis. At the time of renal biopsy eight pa-However, in both studies the carriage rate of IL1RN*2
tients had purpura, in two cases associated with arthritiswas significantly higher in IgAN patients with gross he-
and abdominal pain (Henoch-Scho¨nlein purpura), onematuria than in controls. Carriage of TNF2 also associ-
with only arthritis and two with only abdominal pain.ated with gross hematuria in IgAN patients [23]. The
Four hundred healthy blood donors from same areaimpact of IL-1 and IL-6 gene polymorphism on IgAN
of Finland were used as controls. Blood samples werehas not been reported.
obtained from the Finnish Red Cross Transfusion Center,
It seems possible that both pro- and anti-inflammatory
Tampere, Finland. The donors were adults, their mean
cytokines play a role in the development and progression age (range) was 41 (18 to 60) years; 50% were males
of IgAN. As polymorphisms in the cytokine genes may and 50% females.
determine the production of different cytokines, we in-
vestigated the contribution of IL-1, TNF-, IL-1Ra and Definitions of progression of IgAN, proteinuria
IL-6 gene polymorphism to susceptibility and to progno- and hypertension
sis of IgAN in a well-defined, homogeneous patient pop- The initial measurement of serum creatinine was made
ulation. Our patients were Finns in whom IgAN had at the time of renal biopsy, values 125 mol/L in men
been diagnosed between 1980 and 1990 and who were or 105 mol/L in women being considered normal.
still living in our hospital area. They had been followed Progression of IgAN was defined as an elevation of se-
up for a fairly long period ranging from 6 to 17 (median rum creatinine above the normal level at the assessment
visit and over 20% from baseline. Creatinine values also11) years from renal biopsy.
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Table 1. Allele frequencies of cytokine geneshad been measured at about one-year intervals during
in IgAN patients and controls
the follow-up period and were used in studying the time
Allele frequency %to impaired renal function (defined as above) for the
IgAN Controlpurposes of renal survival analysis. Measurement of uri-
Gene (N  167) (N  400) P valueanary protein excretion was made quantitatively by 24-
IL1b1 51.8 59.3 0.02hour collection; proteinuria was defined as 24-hour uri- IL1b2 48.2 40.8nary protein excretion 1 g. History of gross hematuria
IL1RN*1 59.9 70.1 0.002bwas registered at the time of renal biopsy and history IL1RN*2 38.0 28.9
IL1RN*3 2.1 1.0of gross hematuria was also asked at the time of the
TNF1 91.0 83.7 0.002assessment visit. The criterion for hypertension was the TNF2 9.0 16.2
use of antihypertensive medication or systolic blood IL-6 (G) 45.3 44.6 NSIL-6 (C) 54.3 55.4pressure 	140 mm Hg and/or diastolic blood pressure
Abbreviations are: IgAN, IgA nephropathy; IL, interleukin; TNF, tumor ne-	90 mm Hg measured by sphygmomanometer in sitting
crosis factor.position after rest during hospitalization for the renal a
2 test
b Patients and controls carrying the very infrequent allele ILRN*3 are omittedbiopsy or at assessment.
in the analysis
Analysis of gene polymorphisms
Genomic DNA was isolated from the blood samples
using the salting out method [24]. Polymerase chain reac- librium were calculated using the Arlequin program ver-
sion 2.000 [28].tion (PCR)-based genotyping of IL-1b (base exchange
polymorphism at position511), TNF-a (base exchange
Approval of Ethics Committeepolymorphism at position308), IL-1Ra (variable num-
ber of tandem repeats in intron 2) and IL-6 (base ex- This study was approved by the Ethics Committee of
Tampere University Hospital. All patients gave theirchange G/C at position 174) was carried out as pre-
viously described [19, 25–27]. The IL-1b gene has two informed consent to participate.
alleles at position 511: the more common allele 1
(IL1b1) and the more infrequent IL1b2. The most com-
RESULTS
mon IL-1Ra allele 1 (IL1RN*1) contains four repeats,
Progression of IgAN, occurrence of proteinuria,IL1RN*2 two, IL-1Ra allele 3 (IL1RN*3) five, IL-1Ra
hypertension and gross hematuriaallele 4 (IL1RN*4) three, and IL-1Ra allele 5 (IL1RN*5)
six. The TNF-a gene has two alleles at position308: the One hundred and thirty-six patients (81%) had normal
and 31 (19%) elevated serum creatinine at the time ofmore common allele 1 (TNF1) and the more infrequent
TNF2. renal biopsy. Eighteen of the 136 patients (13%) who
initially had normal serum creatinine showed progres-
Statistical methods sion during the follow-up. In 8 out of the 31 (26%) with
elevated serum creatinine at biopsy there was a furtherThe SPSS package was used for statistical analysis.
Allele frequency was calculated as the number of occur- rise. In another 10 of these 31 (32%), serum creatinine
normalized, but in 13 (42%) the renal functional impair-rences of the test allele in the population divided by the
total number of alleles. The carriage rate was calculated ment was unchanged. Thus, 26 of the study patients
(16%) evinced progression of renal disease according toas the number of individuals carrying at least one copy of
the test allele divided by the total number of individuals. the definition. ESRD (that is, serum creatinine 700
mol/L or requiring dialysis) developed in 10 (6%) pa-Differences in proportions in different patient groups
were compared by chi-square test. Odds ratios (OR) tients 2 to 16 years (median 8 years) after the renal
biopsy. Proteinuria1 g/24 h at biopsy and at assessment(equivalent to approximate relative risk) were calculated
for carriage of different alleles or their combinations in was found in 48 (29%) and 35 (21%) patients, respec-
tively. Sixty-four patients (38%) had a history of grossIgAN patients compared with controls. OR for carriage
of these alleles also were calculated in IgAN patients hematuria. Hypertension was found in 80 patients (48%)
at the time of renal biopsy and in 114 (68%) at thewith and without gross hematuria compared with con-
trols. Confidence limits (CI) of 95% for OR are also assessment visit.
shown. Renal survival analysis in patients carrying the
Cytokine genotypesspecific cytokine gene allele was carried out by the
Kaplan-Meier technique. The difference between sur- The observed distribution of homozygotes and hetero-
zygotes conformed to Hardy-Weinberg expectations. Ta-vival curves was tested by log-rank test. Two-sided P
values are reported, 0.05 being taken as the level of ble 1 shows the allele frequencies of IL-1, TNF-, IL-1Ra
and IL-6 genes in patients and healthy controls. TNFstatistical significance. Tests for Hardy-Weinberg equi-
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Table 4. Risk of IgAN (OR) for subjects carrying differentTable 2. Carriage rate of cytokine alleles in IgAN patients
and controls and odds ratio (OR) of IgAN for carriage combinations of IL1b2 and TNF2 alleles using subjects without
the IL1b2 allele and with the TNF2 allele as referenceof the corresponding allele
Carriage rate % Patientsa Controlsa
IL1b2/TNF2 (N  166) (N  400) OR (95% CI) P valueb
IgAN Control
(N  167) (N  400) OR (95% CI) P valuea IL1b2/TNF2 101 177 4.6 (1.9–11.0) 0.001
IL1b2/TNF2 23 77 2.4 (0.9–6.3) 0.08
IL1b2 74.9 63.5 1.7 (1.1–2.6) 0.009 IL1b2/TNF2 36 98 2.9 (1.2–7.5) 0.02
IL1RN*2 59.9 48.5 1.6 (1.1–2.3) 0.01 IL1b2/TNF2 6 48 Reference
IL1b2 and IL1RN*2 53.3 39.0 1.8 (1.2–2.6) 0.002
a Number of patients or controls with corresponding combination of allelesIL-6 (G) 69.5 70.5 1.0 (0.6–1.4) NS
b
2 testTNF2 17.5 31.3 0.5 (0.3–0.7) 0.001
a
2 test
Table 5. Risk of IgAN (OR) for subjects carrying different
combinations of the IL1RN*2 and TNF2 alleles using subjects
Table 3. Risk of IgAN (OR) for subjects carrying different without the IL1RN*2 allele and with the TNF2 allele as reference
combinations of IL1b2 and IL1RN*2 alleles using subjects with
neither the IL1b2 nor IL1RN*2 allele as reference Patientsa Controlsa
IL1RN*2/TNF2 (N  166) (N  400) OR (95% CI) P valueb
Patientsa Controlsa
IL1RN*2/TNF2 80 130 4.2 (2.0–8.8) 0.001IL1b2/IL1RN*2 (N  167) (N  400) OR (95% CI) P valueb
IL1RN*2/TNF2 20 64 2.1 (0.9–5.0) 0.09
IL1b2/IL1RN*2 89 156 2.0 (1.2–3.2) 0.005 IL1RN*2/TNF2 57 145 2.7 (1.2–5.7) 0.01
IL1b2/IL1RN*2 36 98 1.2 (0.7–2.2) 0.38 IL1RN*2/TNF2 9 61 Reference
IL1b2/IL1RN*2 11 38 1.0 (0.5–2.2) 0.98
a Number of patients or controls with corresponding combination of allelesIL1b2/IL1RN*2 31 108 Reference
b
2 test
a Number of patients or controls with corresponding combination of alleles
b
2 test
Table 6. Risk of IgAN (OR) for subjects carrying different
combinations of IL-1 cluster2a alleles and TNF2 alleles
using subjects without the IL-1 cluster2 alleles andgenotyping could not be carried out in one patient sam-
with the TNF2 allele as referenceple. The rates of carriage of the more infrequent alleles
Patientsb Controlsbare given in Table 2. Excessive carriage of IL1b2 and
IL-1 cluster2a/TNF2 (N  166) (N  400) OR (95% CI) P valuecIL1RN*2 as well as non-carriage of TNF2 was found in
IL-1 cluster2/TNF2 70 107 5.0 (2.4–10.3) 0.001the patient group as compared with the normal controls
IL-1 cluster2/TNF2 19 49 2.9 (1.3–6.7) 0.01(Table 2). Odds ratios with 95% confidence intervals IL-1 cluster2/TNF2 67 168 3.0 (1.5–6.2) 0.002
(CI) of IgAN for carriage of these alleles are also given IL-1 cluster2/TNF2 10 76 Reference
in Table 2. The odds ratio of IgAN for non-carriage of a IL-1 cluster2 means those subjects who carried both IL1b2 and IL1RN*2
alleles, and IL-1 cluster2 were those who did not carry these alleles simultane-TNF2 was 2.1 (1.4 to 3.4).
ously
There was a strong association between carriage of b Number of patients or controls with corresponding combination of alleles
c
2 testIL12 and IL1RN*2 in both patients and controls. In
patients 89 out of 125 (71%) of carriers of IL12 were
carriers of IL1RN*2 versus 11 out of 42 (26%) of non-
carriers of IL12 (
2 test, P 0.001). The corresponding nations of carriage and non-carriage of IL12 and TNF2
figures in controls were 156 out of 254 (61%) versus 38 on the risk of IgAN as compared to non-carriage of
out of 146 (26%) (
2 test, P  0.001). The combined IL12 and carriage of TNF2. The effect of different
action of IL12 and IL1RN*2 or the action of either of combinations of carriage and non-carriage of IL1RN*2
them on the risk of IgAN were therefore compared to and TNF2 on the risk of IgAN as compared to non-
their absence. The results with 95% CI are given in Table carriage of IL1RN*2 and carriage of TNF2 is given in
3, which shows the risk of IgAN to be associated with Table 5. Table 6 shows the effect of different combina-
carriage of both of these alleles. tions of carriage and non-carriage of both IL12 and
Carriage of TNF2 was associated with a decreased IL1RN*2 as well as TNF2 on the risk of IgAN as com-
risk of IgAN (Table 2) and carriage of both IL12 and pared to those who did not carry both of these IL-1
IL1RN*2 with increased risk of this disease (Table 3). cluster genes and carried TNF2.
The IL-1 gene cluster and TNF genes are located in
Prognosis of IgAN and cytokine polymorphismsdifferent chromosomes and are not known to be in link-
age. There was no association between non-carriage of There were no significant differences with respect to
TNF2 and carriage of IL12 and IL1RN*2 in patients presence of hypertension or proteinuria at time of biopsy
or assessment visit according to different cytokine geno-or controls. Table 4 shows the effect of different combi-
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Table 7. Carriage rates of various cytokine alleles according to history of gross hematuria
Clinical picture
Carriage rate in pts without Carriage rate in pts with
gross hematuria % gross hematuria %
Cytokine allele (N  103) (N  64) OR (95% CI)a P valuea
IL1b2 81.6 64.1 2.5 (1.2–5.1) 0.01
IL1RN*2 63.1 54.7 1.4 (0.8–2.7) 0.3
TNF2 20.4 12.7 1.7 (0.7–4.3) 0.2
IL-6 (174) G 71.8 65.6 0.7 (0.4–1.5) 0.4
a
2 test; patients without gross hematuria are compared to those with gross hematuria
types or carriage of different cytokine alleles. Progres- neous and representative of IgAN, and the criteria for
biopsy were applied consistently throughout the studysion or renal survival (studied by Kaplan-Meier tech-
nique) did not differ significantly according to different period. Our policy has been to perform a renal biopsy
also in cases of minor urinary abnormalities. This is re-cytokine genotypes or carriage of different cytokine al-
leles (data not shown). No deleterious effects were found flected in a fairly favorable prognosis of IgAN; the pat-
tern is, however, quite similar to that in another Euro-on prognosis of carriage of IL1b2, IL1RN*2, or both of
these alleles, neither of carriage of TNF2 or either of the pean study [29]. Furthermore, the strength of the present
study was a large study population with a long follow-IL-6 alleles. Progression was observed in 15% of carriers
versus 16% of non-carriers of IL1b2, in 13% of carriers up and a low number of patients lost to follow-up. Thirty
of the original 223 patients had died during follow-upversus 19% of non-carriers of IL1RN*2, in 12% of carri-
ers versus 19% of non-carriers of both of these alleles, (5 of them from uremia and 25 of other causes [3])
and their cytokine gene polymorphism was not analyzed.and in 10% of carriers versus 17% of non-carriers of
TNF2. This may affect the results with respect to progression,
which was more common among those who died. How-
Gross hematuria and cytokine polymorphisms ever, 26 patients could be analyzed who showed progres-
sion during the follow-up.Carriage of IL1b2 differed according to the history
The definitions of impaired renal function and pro-of gross hematuria (Table 7). Carriage of IL1b2 in the
gression of IgAN were based on serum creatinine levels,patients who did not present gross hematuria differed
which were used routinely in the follow-up of all patientssignificantly from controls (81.6% in patients vs. 63.5%
[3]. It is well established that substantial reductions inin controls; P  0.001), while there was no significant
renal function may occur before serum creatinine be-difference in those with gross hematuria. Likewise, car-
comes abnormal; thus it is possible that in some patientsriage of IL1RN*2 differed significantly from controls
defined as having normal renal function it was actuallyonly in the subgroup of patients without gross hematuria
slightly decreased. We also included an elevation of cre-(63.1% in patients vs. 48.5% in controls; P  0.008).
atinine of over 20% in the definition of progression ofCarriage of TNF2 was significantly less frequent in pa-
IgAN to avoid misclassification of patients with stabletients both without (20.4%) and with (12.7%) gross he-
disease.maturia as compared to controls (31.3%; P  0.03 and
There are no earlier reports of carriage of IL1b2 inP  0.002, respectively).
IgAN, but carriage of IL1RN*2 has been studied. In
accord with our results Shu and colleagues found an
DISCUSSION association between carriage of IL1RN*2 and IgAN [23].
This study illustrates the association between carriage The carriage rates of IL1RN*2 in both patients and con-
trols, however, differed from our current study: 4% inof IL12, IL1RN*2 and non-carriage of TNF2 and
susceptibility to IgAN. Carriage of both IL12 and the controls and 20% in the patients in their study [23]
versus 49% in controls and 60% in patients our study.IL1RN*2 together with non-carriage of TNF2 was associ-
ated with highly increased risk of IgAN. None of the This discrepancy probably reflects racial differences and
shows that the carriage of IL1RN*2 per se cannot havecytokine allele polymorphisms studied affected the prog-
nosis of IgAN. an independent role in the etiology and pathogenesis of
IgAN. In an earlier study Liu and coworkers found anReferral patterns and indications for renal biopsy vary
in different studies, which probably influences the pro- association between excessive carriage of IL1RN*2 and
Henoch-Scho¨nlein nephritis and IgAN with recurrentportion of patients with progressive disease. Also, racial
differences and management of patients affect the out- gross hematuria, but not with other clinical patterns [22].
This is quite the opposite of our results, where an associa-come of IgAN. Our patient population was homoge-
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tion between carriage of IL1RN*2 and IgAN was found patients with gross hematuria the carriage of TNF2 was
rare. These opposite results are difficult to interpret. Theonly in patients who did not have gross hematuria. Liu
and coworkers [22] found that the carriage rate of occurrence of gross hematuria was different in these
studies (38% in our study vs. 12% in the study by ShuIL1RN*2 again was different from our study results and
those of Shu and colleagues [23]. They reported carriage and coworkers), which may affect the results. Although
increased TNF transcriptional activity has been associ-rate of 25% in controls, 27% in all IgAN patients and
35% in those with recurrent gross hematuria [22]. An ated with the TNF2 (308) allele, it has not been shown
to have any relationship to circulating levels of TNF-,association between carriage of IL1RN*2 and diabetic
nephropathy also has been reported [21], and in the but local concentration of TNF- at the site of inflamma-
tion may be influenced [39]. In patients with systemicCaucasian population in question the carriage rate in
controls was quite similar (42%) to our observation. lupus erythematosus TNF2 is associated with a reduced
risk of lupus nephritis [39]. TNF- has a dual function,An association between IL1RN*2 and ESRD due to
diabetes or other diseases has been found by genetic being pro-inflammatory in the initial infection and anti-
inflammatory or immunoregulatory in the later phaseslinkage analysis in African Americans as well [30].
Our study demonstrates that simultaneous carriage of of the response [39]. This may be important in interpre-
ting the results of the present study in the case of patientsboth IL1b2 and IL1RN*2 increases the risk of IgAN.
The mechanism underlying this association remains a with chronic inflammation in their kidneys triggered by
an unknown antigen(s).matter of speculation. Pro-inflammatory cytokines, espe-
cially IL-1, are of central importance in T- and B-cell The present study showed no association between pro-
gression of IgAN and any of the cytokine gene polymor-help and the initiation, for example, of humoral immune
responses such as IgA production. Enhanced IgA re- phisms studied. In contrast to our results, Shu et al found
an association between carriage of IL1RN*2 and pro-sponses have been observed after parental or oral vacci-
nation of IgAN patients [31, 32]. In IgAN, IgA is defec- gression [23]. Their definition of progression differed
from ours. The most striking difference between thesetively glycosylated [33–35] and the deposition in the
mesangium is followed by mesangial proliferation and studies was the proportion of patients who had reached
ESRD: 31% in their study as compared to 6% in ours.chronic glomerular inflammation. IL-1 is expressed in
the glomeruli of these patients [8, 10], and it may be While the indications for renal biopsy differed less mark-
edly, only 52% of all patients diagnosed were studiedinvolved in mesangial cell proliferation [36] and extracel-
lular matrix production [37]. IL-1Ra also plays a role as with regard to cytokine polymorphism in their study
compared to 75% here. Differences in patient materiala natural blocking agent in the inflammation mediated
by IL-1. In IgAN the association between alleles of the may partly explain these discrepant results. Shu and co-
workers also found no association between TNF (308)IL-1 cluster genes, IL1b2 and IL1RN*2, has not pre-
viously been reported. The risk of IgAN was associated polymorphism and progression [23]. It also is possible
that the cytokine polymorphism found to be associatedwith simultaneous carriage of IL1b2 and IL1RN*2, but
not with carriage of either IL1b2 or IL1RN*2 alone. with susceptibility has no effect on disease severity and
progression, and that nonimmunologic mechanisms suchThis may be explained by IL1RN*2, or an allele closely
associated to it, being probably the strongest up-regula- as hypertension, proteinuria and metabolic disturbances
play a more important role.tor of in vitro IL-1 levels [38], and thus, the effect of
carrying both these alleles is probably pro-inflammatory. In conclusion, the present study shows that carriage
of IL1b2 together with IL1RN*2 increases the risk ofAlthough there are several hypothetical links between
IL-1, IL1Ra and IgAN, it is possible that both IL1b2 IgAN twofold as compared to non-carriage of either of
these alleles. Carriage of TNF2 was found to be protec-and IL1RN*2 are markers of a linked locus that is the
real disease-associated locus. The observed association tive against IgAN. Carriage of IL1b2 and IL1RN*2 to-
gether with non-carriage of TNF2 increased the risk ofbetween the alleles of the IL-1 cluster genes or of TNF
genes and IgAN cannot be explained by the earlier find- IgAN fivefold, suggesting that different cytokines proba-
bly function in concert in the development of IgAN. Noings of Gharavi and coworkers on the linkage of IgAN
to chromosome 6q22-q23 [6], as the locations of these association was found between progression and cytokine
gene polymorphisms.cytokine genes are different.
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